1. What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 
Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani, Frédéric Staerman, Claude C Schulman 
European Urology Supplements 
Volume 6, Issue 4, Pages (March 2007)
DOI: /j.eursup
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
Age-related incidence of prostate cancer and mortality rate due to prostate cancer according to the National Cancer Institute Surveillance, Epidemiology and End Results Program (SEER) database.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
A significantly higher percentage of men was cancer positive and presented with a Gleason score ≥7 in the group with a Prostate-Specific Antigen (PSA) level of 4–10ng/ml compared to those with a level of <4ng/ml (p<0.001) [3].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

4. Fig. 3
There were no significant differences between external-beam radiation therapy (EBRT) and radical prostatectomy (RP) in terms of survival rates or clinical disease progression after a follow-up period of 67 mo [9].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

5. Fig. 4
Patients taking tadalafil showed a significant increase in mean scores of International Index of Erectile Function (improvement in erectile function and successful intercourse) versus placebo [14].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

6. Fig. 5
In patients receiving a single administration of zoledronic acid (ZA) lumbar spinal bone mineral density (BMD) was significantly increased compared to patients receiving placebo (p<0.001) [27].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

7. Fig. 6
More patients with hormone-resistant prostate cancer (HRPC) receiving the combination of docetaxel and estramustine have a prostate-specific antigen (PSA) decrease ≥50% and a PSA normalisation compared to those receiving docetaxel alone [30].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions